<p>Efficacy and Safety of Percutaneous Ozone Injection Around Gasserian Ganglion for the Treatment of Trigeminal Neuralgia: A Multicenter Retrospective Study</p>

Abstract

Background: Ozone injection around Gasserian ganglion (OIAGG) has been reported to be an effective treatment for trigeminal neuralgia (TN); however, there remain areas for improvement. To overcome one of these limitations, a multicenter examination of application would be extremely helpful. Objective: The goal of this report was to assess the efficacy of OIAGG for refractory TN across multiple centers and to explore factors predictive of successful treatment. Design: A multicenter, retrospective study. Setting: The study was conducted across 3 pain centers across China. Patients and Methods: A total of 103 subjects from 3 pain centers were enrolled in the study. An ozone-oxygen mixture gas at a concentration of 30 µg/mL was injected into the area around the Gasserian ganglion performed under C-arm X-ray guidance. Primary outcome measures included a pain assessment using a visual analog scale (VAS) and the Barrow Neurological Institute (BNI) pain intensity scale. Clinical assessment of patients for these outcome measures was performed at pretreatment, post-treatment, 6 months, 1 year and 2 years after the OIAGG. Results: Successful pain relief was defined as a score within BNI grades I-IIIa. The pain relief rates at post-treatment, 6 months, 1 year and 2 years after the procedure were 88.35%, 86.87%, 84.46% and 83.30%, respectively. The VAS at each observation time point was significantly different from the preoperative levels (P<0.05). Logistic regression analysis showed that previous nerve damage had a significant effect on the treatment results. No significant complications or side effects were found during or after treatment. Conclusion: This multicenter research confirms our previous single center results that OIAGG is both effective and safe for patients with TN.

Chemogenetic inhibition of trigeminal ganglion neurons attenuates behavioural and neural pain responses in a model of trigeminal neuropathic pain

“…The cell bodies of all primary trigeminal afferent nociceptors lie within the trigeminal ganglia (TG). Therefore, in addition to having an important role in pathologic pain, the TG is a strategic locus where afferent input can be manipulated (Gao et al, 2020;Vit et al, 2009). Viral deliverymediated gene therapy in TG offers a potentially attractive therapeutic approach for treatment of PTTN (Huang et al, 2011).…”

Therapeutic effect of duloxetine combined with ozone trigger point injection on fibromyalgia---A retrospective observational study

“…However, ozone's merits of safe, convenient and green have greatly expanded its clinical applicability [21]. Now, ozone is widely used in patients who need nerve block and local trigger point injection [22,23]. The treatment of FM is majorly based on amitriptyline, but more and more data suggested that duloxetinebased treatment is more effective with smaller side effects [24,25].…”

Clinical Efficacy of Percutaneous Balloon Compression Combined with Carbamazepine in the Treatment of Trigeminal Neuralgia: A Retrospective Study

“…(2) The clinical efficacy of the two groups was compared through 1 month follow-up after surgical treatment. The Barrow Neurological Institute (BNI) [8] pain score was used to evaluate the degree of postoperative pain. BNI scores were divided into five levels: Grade I, no pain and no medication required; Grade II, patients have occasional pain but are not taking any medications; Grade Ⅲ, patients displayed some pain, which could be controlled by drugs.…”